Denosumab in Subjects With Giant Cell Rich Tumors of Bone
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
An open-label, multi-center, phase 2 study of the efficacy of denosumab in subjects with
giant cell rich tumors of bone. The population will consist of subjects with the following
tumor types: aneurysmal bone cysts (ABC), giant cell granuloma (GCG) and other giant cell
rich lesions (primary bone, non-malignant).